Compare Tidewater Inc (TDW) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tidewater Inc vs TransMedics Group Inc — how do they compare? Tidewater Inc trades at $85.42 (market cap $4.21B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Tidewater Inc is the larger of the two by market cap, and Tidewater Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tidewater Inc for 26 Days and TransMedics Group Inc for 24 Days on average.
| TDW | TMDX | |
|---|---|---|
Market Cap | $4.21B | $2.74B |
Volume | 590,005 | 949,331 |
Sector | Energy | Health |
52-Week High | $100.61 | $150.42 |
52-Week Low | $47.29 | $61.99 |
Typical Hold Time | 26 Days | 24 Days |
Enterprise Value | $4.25B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tidewater (TDW) trades at $84.70, up 1.56% today, with a bullish technical signal from moving averages and a consensus analyst price target of $105.50. The company reported strong 2025 results with $1.35B revenue and $334.66M net income, though 2026 shows a decline. Recent news includes the completion of the Wilson Sons Ultratug acquisition and significant institutional buying by BlackRock.
The stock offers upside to the price target but faces risks from earnings volatility, as seen in recent quarterly misses, and exposure to energy market cycles. Investor sentiment is mixed with a majority hold rating from analysts, indicating cautious optimism amid operational execution challenges.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
